1. CD109 and squamous cell carcinoma
- Author
-
Qiang Liu, Yoshiki Murakumo, Ju Liu, Fengyun Dong, and Ruixia Qi
- Subjects
0301 basic medicine ,Poor prognosis ,lcsh:Medicine ,Review ,Squamous cell carcinoma (SCC) ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,Metastasis ,STAT3 ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Antigens, CD ,Transforming Growth Factor beta ,Humans ,Medicine ,Basal cell ,skin and connective tissue diseases ,neoplasms ,TGF-β signaling pathway ,High rate ,chemistry.chemical_classification ,biology ,business.industry ,lcsh:R ,General Medicine ,medicine.disease ,CD109 ,stomatognathic diseases ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Potential biomarkers ,Carcinoma, Squamous Cell ,biology.protein ,Cancer research ,business ,Glycoprotein ,Signal Transduction - Abstract
Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs.
- Published
- 2018